Hormonal
Thyroid hormone receptor beta (THRβ) agonists and specific thyroid hormone metabolites (T2, T1AM) reduce hepatic lipid content and serum cholesterol in NAFLD and hypercholesterolemia models by stimulating fatty acid oxidation and cholesterol clearance without the cardiac side effects of natural thyroid hormones.
Current standard care for NAFLD focuses on lifestyle changes. However, emerging research indicates that specific thyroid hormone analogs and metabolites (like T2 and T1AM) are being developed to treat liver fat and high cholesterol. These are not yet available as standard treatments but represent a promising future direction for patients who do not respond to lifestyle interventions. Do not self-administer thyroid hormones; consult a specialist about clinical trials if eligible.
TH receptor β analogs designed to have less side effects than the natural hormone are currently being tested in phase II clinical studies for NAFLD and hypercholesterolemia. The TH metabolites, 3,5-diiodo-L-thyronine (T2) and T1AM (3-iodothyronamine), have different beneficial effects on lipid metabolism compared with triiodothyronine (T3)... TH-based therapies show clinical promise for the treatment of NAFLD and hypercholesterolemia.
Why this rating
The paper is a review summarizing animal models and early-phase clinical trials; it does not present large-scale Phase III human data.
Source
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
Rohit A. Sinha et al. · Thyroid · 2019
DOI 10.1089/thy.2018.0664
More from this paper
- Thyroid-stimulating hormone (TSH) directly promotes hepatic lipogenesis and cholesterol biosynthesis, worsening NAFLD and hypercholesterolemia, independent of its role in stimulating thyroid hormone production.Moderate
- Glucagon-Thyroid Hormone (T3) conjugates reduce liver fat and improve dyslipidemia in obesity models by targeting the liver specifically, avoiding the cardiac and skeletal side effects of systemic T3 therapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →